Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Bullboard (CSE:AGN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by StockHawk1on Jan 23, 2023 4:56pm

Article highlights AGN's DMT-Stroke Research

Algernon Pharmaceuticals (AGN.c AGNPF) looks like it is bouncing back, closing in the green today. The Green Market Report recently featured the pharma tech company, highlighting its ongoing ...more  
167
Post by Unicorn9000on Jan 22, 2023 5:54am

Wow $2.00 plus now

It used to be .15 cents. people still here?
251
Post by SkywalkerofLukeon Jan 20, 2023 5:10pm

Video on Recent News

AGN.c AGNPF CEO interview on news that they dosed the first subject in their Phase 1 DMT Clinical Stroke Study. The resulting data generated will help AGN to plan both a Phase 2 acute stroke and ...more  
148
Post by StockHawk1on Jan 20, 2023 4:44pm

New CEO interview

Algernon Pharmaceuticals' (AGN.c AGNPF) CEO, Chis Moreau, went on the Radius Research YT channel yesterday to talk about the company's DMT Program. AGN has started its Phase 1 DMT Clinical ...more  
155
Discussion
Post by bmreedon Jan 20, 2023 2:44pm

News Update: $AGN CEO Christopher Moreau and Radius Research

News Update: Algernon Pharmaceuticals $AGN w CEO Christopher Moreau - Pitch, Deep Dive and Q&A - https://youtu.be/gW5hOpC6Xas   CEO Chis Moreau provides update on AP-188 DMT ...more  
148
Comment by C10H12N2on Jan 20, 2023 1:19pm

RE:The Branded Cattle/Catalyst That Never Gets Old

Correction: Multiply the current outstanding shares by 200 (Two Hundred).
45
Discussion
Post by C10H12N2on Jan 20, 2023 8:38am

The Branded Cattle/Catalyst That Never Gets Old

Just Remember: Anyone wanting to keep track of how many shares of Algernon Pharmaceuticals have been diluted by Moreau - simply take the current outstanding shares and multiply it by 2 (Two). That is ...more  
125
Discussion
Post by StockHawk1on Jan 19, 2023 4:55pm

Possible catalysts in Q3

The pharma development company Algernon Pharmaceuticals (AGN.c AGNPF) announced last week that it is planning to conduct the Phase 2b clinical study of its Ifenprodil drug. The 180-patient 90-day ...more  
156
Post by StockDoctor101on Jan 19, 2023 11:34am

AGN phase 1 DMT study

AGN is advancing phase 1 DMT clinical stroke study and the first subject has been dosed. Will be helpful in planning for phase 2 as well. AGN.c is the first company in the world to investigate DMT for ...more  
86
Post by StockHawk1on Jan 18, 2023 3:44pm

AGN doses first DMT participant (video)

Algernon Pharmaceuticals (AGN.c AGNPF) has started the first phase of its clinical study on DMT for the treatment of stroke. Currently, healthy patients are being given DMT to identify a safe and ...more  
134
Post by Justdosomeddon Jan 18, 2023 1:42pm

First Company to Begin Trials for DMT on Stroke

Phase 1 of the DMT stroke study has just begun, with the first patient being dosed yesterday. The first part of the study will use a single-escalating dose design aimed at identifying a safe and ...more  
95
Post by StockHawk1on Jan 17, 2023 3:11pm

AGN begins Phase 1 DMT-stroke study

Algernon Pharmaceuticals (AGN.c AGNPF) has dosed the first subject in its Phase 1 clinical study of DMT for the treatment of stroke.  In this phase of the study, AGN is dosing healthy patients ...more  
132
Post by SkywalkerofLukeon Jan 17, 2023 2:03pm

News

AGN.c AGNPF progressing their Phase 1 DMT Clinical Stroke Study with the news that they dosed their first subject. The resulting data generated will help AGN to plan both a Phase 2 acute stroke and ...more  
126
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities